Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Profit After Tax: 2014-2025

Historic Profit After Tax for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$71.3 million.

  • Ascendis Pharma A's Profit After Tax rose 34.55% to -$71.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$255.9 million, marking a year-over-year increase of 44.67%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Profit After Tax is -$71.3 million, which was down 62.11% from -$44.0 million recorded in Q2 2025.
  • Ascendis Pharma A's Profit After Tax's 5-year high stood at -$41.1 million during Q4 2024, with a 5-year trough of -$211.6 million in Q4 2022.
  • Its 3-year average for Profit After Tax is -$104.2 million, with a median of -$108.9 million in 2024.
  • As far as peak fluctuations go, Ascendis Pharma A's Profit After Tax tumbled by 85.96% in 2022, and later surged by 62.66% in 2025.
  • Ascendis Pharma A's Profit After Tax (Quarterly) stood at -$121.3 million in 2021, then plummeted by 74.41% to -$211.6 million in 2022, then spiked by 55.83% to -$93.5 million in 2023, then skyrocketed by 56.02% to -$41.1 million in 2024, then surged by 34.55% to -$71.3 million in 2025.
  • Its Profit After Tax was -$71.3 million in Q3 2025, compared to -$44.0 million in Q2 2025 and -$99.5 million in Q1 2025.